

# Michael I Koukourakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3508478/publications.pdf>

Version: 2024-02-01

283  
papers

22,383  
citations

16791

66  
h-index

11282

141  
g-index

283  
all docs

283  
docs citations

283  
times ranked

36842  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining the past and present to advance immuno-radiotherapy of cancer. <i>International Reviews of Immunology</i> , 2023, 42, 26-42.	1.5	8
2	Postoperative hypofractionated accelerated radiotherapy (HypoAR) for locally advanced rectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 493-498.	0.6	1
3	Lipophagy-Related Protein Perilipin-3 and Resistance of Prostate Cancer to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 401-414.	0.4	8
4	Loss of HLA-class-I expression in non-small-cell lung cancer: Association with prognosis and anaerobic metabolism. <i>Cellular Immunology</i> , 2022, 373, 104495.	1.4	8
5	Expression of CD47 and SIRP $\alpha$ Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1801.	1.7	15
6	Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisit of therapeutic principles. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188704.	3.3	24
7	Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 13-23.	1.1	16
8	Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head-Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy. <i>Current Oncology</i> , 2022, 29, 4274-4284.	0.9	9
9	Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients. <i>Radiation Oncology Journal</i> , 2022, 40, 151-161.	0.7	0
10	Aldehyde Dehydrogenase 1B1 Is Associated with Altered Cell Morphology, Proliferation, Migration and Chemosensitivity in Human Colorectal Adenocarcinoma Cells. <i>Biomedicines</i> , 2021, 9, 44.	1.4	10
11	6-Nitroquinazolin <sup>4(3H)</sup> one Exhibits Photodynamic Effects and Photodegrades Human Melanoma Cell Lines. A Study on the Photoreactivity of Simple Quinazolin <sup>4(3H)</sup> ones. <i>Photochemistry and Photobiology</i> , 2021, 97, 826-836.	1.3	6
12	Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy. <i>Chemotherapy</i> , 2021, 66, 82-86.	0.8	8
13	Is Locally Advanced Head-Neck Cancer One More Candidate for Accelerated Hypofractionation?. <i>Anticancer Research</i> , 2021, 41, 467-475.	0.5	5
14	Volumetric modulated arc therapy (VMAT) craniospinal image-guided radiotherapy and chemotherapy for high-risk medulloblastoma in adults: A case report with analysis of the technique. <i>Journal of Case Reports and Images in Oncology</i> , 2021, 7, 1-8.	0.0	0
15	Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103226.	2.0	19
16	Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. <i>BJR   case Reports</i> , 2021, 7, 20200170.	0.1	1
17	Regulatory tumor-infiltrating lymphocytes prevail in endometrial tumors with low vascular survival ability. <i>Immunobiology</i> , 2021, 226, 152078.	0.8	4
18	Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 3989-3995.	0.5	15

#	ARTICLE	IF	CITATIONS
19	Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine. <i>Medical Oncology</i> , 2021, 38, 116.	1.2	9
20	The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer. <i>Cancer &amp; Metabolism</i> , 2021, 9, 28.	2.4	18
21	Apalutamide radio-sensitisation of prostate cancer. <i>British Journal of Cancer</i> , 2021, 125, 1377-1387.	2.9	4
22	Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost. <i>Current Oncology</i> , 2021, 28, 3474-3487.	0.9	4
23	Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres. <i>Anticancer Research</i> , 2021, 41, 5481-5488.	0.5	1
24	Immunohistochemical detection of senescence markers in human sarcomas. <i>Pathology Research and Practice</i> , 2020, 216, 152800.	1.0	9
25	Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. <i>Life Sciences</i> , 2020, 259, 118389.	2.0	34
26	A Novel Lipofuscin-detecting Marker of Senescence Relates With Hypoxia, Dysregulated Autophagy and With Poor Prognosis in Non-small-cell-lung Cancer. <i>In Vivo</i> , 2020, 34, 3187-3193.	0.6	11
27	iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3276.	1.7	11
28	Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia?. <i>Dose-Response</i> , 2020, 18, 155932582095135.	0.7	2
29	Rectal cancer induces a regulatory lymphocytic phenotype in the tumor-draining lymph nodes to promote cancer cell installation. <i>Immunologic Research</i> , 2020, 68, 363-372.	1.3	5
30	Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. <i>British Journal of Cancer</i> , 2020, 122, 1205-1210.	2.9	24
31	Tumor microenvironment, immune response and post-radiotherapy tumor clearance. <i>Clinical and Translational Oncology</i> , 2020, 22, 2196-2205.	1.2	24
32	Radio-Immunotherapy: A Case Report of "Abscopal Hyper-Progression". <i>Cureus</i> , 2020, 12, e10117.	0.2	2
33	Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy. <i>International Journal of Radiation Biology</i> , 2019, 95, 408-426.	1.0	48
34	Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. <i>Medical Oncology</i> , 2019, 36, 76.	1.2	36
35	Hypofractionated Accelerated Chemo-radiotherapy (Chemo-HypoAR) With Cisplatin and Liposomal Doxorubicin for the Treatment of Patients With Uterine Sarcomas. <i>In Vivo</i> , 2019, 33, 1621-1624.	0.6	3
36	"Stemness" and "senescence" related escape pathways are dose dependent in lung cancer cells surviving post irradiation. <i>Life Sciences</i> , 2019, 232, 116562.	2.0	14

#	ARTICLE	IF	CITATIONS
37	FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma. <i>Experimental Lung Research</i> , 2019, 45, 76-83.	0.5	24
38	Angiogenic regeneration defines loco-regional recurrence following pre-operative radio-chemotherapy for rectal cancer: a pilot study. <i>Molecular Biology Reports</i> , 2019, 46, 2147-2152.	1.0	2
39	Characterization of the "Autophagic Flux" in Prostate Cancer Tissue Biopsies by LC3A/LAMP2a Immunofluorescence and Confocal Microscopy. <i>Methods in Molecular Biology</i> , 2019, 1880, 555-560.	0.4	3
40	Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. <i>Anti-Cancer Drugs</i> , 2018, 29, 323-333.	0.7	17
41	SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. <i>Investigational New Drugs</i> , 2018, 36, 773-781.	1.2	13
42	Autophagic flux response and glioblastoma sensitivity to radiation. <i>Cancer Biology and Medicine</i> , 2018, 15, 260.	1.4	17
43	LC3A, LC3B and Beclin-1 Expression in Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6827-6833.	0.5	29
44	Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of <i>miR34a</i> and <i>miR200</i> . <i>Anticancer Research</i> , 2018, 38, 5739-5745.	0.5	16
45	Hypoxia Inducible Factor Expression and Angiogenesis " Analysis in the Pituitary Gland and Patterns of Death. <i>In Vivo</i> , 2018, 32, 185-190.	0.6	4
46	Amifostine Protects Mouse Liver Against Radiation-induced Autophagy Blockage. <i>Anticancer Research</i> , 2018, 38, 227-238.	0.5	8
47	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer. <i>Medical Oncology</i> , 2017, 34, 20.	1.2	10
48	Differential effect of hypoxia and acidity on lung cancer cell and fibroblast metabolism. <i>Biochemistry and Cell Biology</i> , 2017, 95, 428-436.	0.9	12
49	Trachycladines and Analogues: Synthesis and Evaluation of Anticancer Activity. <i>ChemMedChem</i> , 2017, 12, 448-455.	1.6	3
50	Transcription Factor EB Expression in Early Breast Cancer Relates to Lysosomal/Autophagosomal Markers and Prognosis. <i>Clinical Breast Cancer</i> , 2017, 17, e119-e125.	1.1	34
51	Metabolic cooperation between co-cultured lung cancer cells and lung fibroblasts. <i>Laboratory Investigation</i> , 2017, 97, 1321-1331.	1.7	37
52	Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 932-938.	1.0	34
53	Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. <i>Experimental Lung Research</i> , 2017, 43, 167-174.	0.5	53
54	Thermogenic protein UCP1 and UCP3 expression in non-small cell lung cancer: relation with glycolysis and anaerobic metabolism. <i>Cancer Biology and Medicine</i> , 2017, 14, 396.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Inhibition of IKK-NF $\kappa$ B pathway sensitizes lung cancer cell lines to radiation. <i>Cancer Biology and Medicine</i> , 2017, 14, 293.	1.4	20
56	Assessment of Radiobiological $\alpha/\beta$ Ratio in Lung Cancer and Fibroblast Cell Lines Using Viability Assays. <i>In Vivo</i> , 2017, 31, 175-180.	0.6	4
57	Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy. <i>British Journal of Cancer</i> , 2016, 115, 312-321.	2.9	28
58	Technical Note: Partial body irradiation of mice using a customized PMMA apparatus and a clinical 3D planning/LINAC radiotherapy system. <i>Medical Physics</i> , 2016, 43, 2200-2206.	1.6	7
59	Hypoxia-inducible proteins HIF1 $\alpha$ and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. <i>International Journal of Radiation Biology</i> , 2016, 92, 353-363.	1.0	55
60	Normal tissue radioprotection by amifostine via Warburg-type effects. <i>Scientific Reports</i> , 2016, 6, 30986.	1.6	27
61	Aldehyde dehydrogenase 3A1 promotes multi-modality resistance and alters gene expression profile in human breast adenocarcinoma MCF-7 cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 77, 120-128.	1.2	24
62	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
63	Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. <i>British Journal of Cancer</i> , 2016, 114, 485-496.	2.9	61
64	Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0137675.	1.1	135
65	Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 268-274.	1.0	28
66	Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 98-105.	0.9	79
67	Survival Fraction at 2 Gy and $\gamma$ H2AX Expression Kinetics in Peripheral Blood Lymphocytes From Cancer Patients: Relationship With Acute Radiation-Induced Toxicities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 667-674.	0.4	20
68	Fever-Range Hyperthermia vs. Hypothermia Effect on Cancer Cell Viability, Proliferation and HSP90 Expression. <i>PLoS ONE</i> , 2015, 10, e0116021.	1.1	42
69	Important Role of Autophagy in Endothelial Cell Response to Ionizing Radiation. <i>PLoS ONE</i> , 2014, 9, e102408.	1.1	27
70	Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. <i>British Journal of Cancer</i> , 2014, 110, 2209-2216.	2.9	16
71	Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. <i>British Journal of Cancer</i> , 2014, 110, 2217-2223.	2.9	69
72	Autophagy and lysosomal related protein expression patterns in human glioblastoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 1468-1478.	1.5	80

#	ARTICLE	IF	CITATIONS
73	Evaluation of the Alamarblue Assay for Adherent Cell Irradiation Experiments. Dose-Response, 2014, 12, dose-response.1.	0.7	39
74	Gamma histone 2AX ( $\gamma$ -H2AX) as a predictive tool in radiation oncology. Biomarkers, 2014, 19, 167-180.	0.9	42
75	Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis. Medical Oncology, 2014, 31, 945.	1.2	31
76	Autophagy proteins in prostate cancer: Relation with anaerobic metabolism and Gleason score11The study was financially supported by the Tumor and Angiogenesis Research Group.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 39.e11-39.e18.	0.8	52
77	Histological changes after radiation therapy in patients with lung cancer: a prospective study. Anticancer Research, 2014, 34, 3119-24.	0.5	14
78	Postmastectomy Hypofractionated and Accelerated Radiation Therapy With (and Without) Subcutaneous Amifostine Cytoprotection. International Journal of Radiation Oncology Biology Physics, 2013, 85, e7-e13.	0.4	42
79	Establishment and validation of a method for multi-dose irradiation of cells in 96-well microplates. Biochemical and Biophysical Research Communications, 2013, 431, 456-459.	1.0	13
80	High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC). Angiogenesis, 2013, 16, 343-351.	3.7	15
81	Dose Escalation of Amifostine for Radioprotection During Pelvic Accelerated Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 338-343.	0.6	10
82	Autophagy and hypoxia in colonic adenomas related to aggressive features. Colorectal Disease, 2013, 15, e223-30.	0.7	15
83	Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. Apmis, 2013, 121, 592-604.	0.9	23
84	The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biology and Therapy, 2012, 13, 1284-1289.	1.5	55
85	Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. British Journal of Cancer, 2012, 107, 1044-1050.	2.9	16
86	Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC). Urologic Oncology: Seminars and Original Investigations, 2012, 30, 813-820.	0.8	10
87	Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. British Journal of Cancer, 2012, 106, 846-853.	2.9	122
88	Radiation damage and radioprotectants: new concepts in the era of molecular medicine. British Journal of Radiology, 2012, 85, 313-330.	1.0	110
89	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
90	Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2 $\alpha$ and survival. Clinical and Experimental Metastasis, 2012, 29, 11-17.	1.7	14

#	ARTICLE	IF	CITATIONS
91	Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. <i>Anticancer Research</i> , 2012, 32, 4561-8.	0.5	9
92	Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4892-4900.	3.2	119
93	Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. <i>Cytokine</i> , 2011, 53, 370-375.	1.4	27
94	Lung autophagic response following exposure of mice to whole body irradiation, with and without amifostine. <i>Biochemical and Biophysical Research Communications</i> , 2011, 404, 552-558.	1.0	9
95	Amifostine-Related Fever-Rash During Fractionated Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 281-285.	0.6	5
96	Beclin-1 and LC3A expression in cutaneous malignant melanomas. <i>Melanoma Research</i> , 2011, 21, 188-195.	0.6	67
97	Light-Chain 3A Autophagic Activity and Prognostic Significance in Non-small Cell Lung Carcinomas. <i>Chest</i> , 2011, 140, 127-134.	0.4	75
98	Long-term survival of a patient with multiple abdominal metastasis from endometrial carcinoma treated with multi-portal conformal re-irradiation and chemotherapy. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 45-47.	0.6	3
99	High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. <i>Gynecologic Oncology</i> , 2011, 123, 147-151.	0.6	64
100	Autophagy patterns and prognosis in uveal melanomas. <i>Modern Pathology</i> , 2011, 24, 1036-1045.	2.9	46
101	The CD44+/CD24 <sup>low</sup> phenotype relates to a "triple-negative" state and unfavorable prognosis in breast cancer patients. <i>Medical Oncology</i> , 2011, 28, 745-752.	1.2	120
102	Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). <i>Medical Oncology</i> , 2011, 28, 1356-1362.	1.2	5
103	Bevacizumab, Capecitabine, Amifostine, and Preoperative Hypofractionated Accelerated Radiotherapy (HypoArc) for Rectal Cancer: A Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 492-498.	0.4	28
104	"Autophagic flux" in normal mouse tissues: Focus on endogenous LC3A processing. <i>Autophagy</i> , 2011, 7, 1371-1378.	4.3	59
105	Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS): What is destined for the atypical endometrial hyperplasia?. <i>Autophagy</i> , 2011, 7, 74-82.	4.3	49
106	Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. <i>Anticancer Research</i> , 2011, 31, 1745-51.	0.5	6
107	c-erbB-2 and the "triple-state" in early breast carcinomas. <i>Medical Oncology</i> , 2010, 27, 578-584.	1.2	5
108	Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 9-15.	0.4	29

#	ARTICLE	IF	CITATIONS
109	Concurrent Liposomal Cisplatin (Lipoplatin), 5-Fluorouracil and Radiotherapy for the Treatment of Locally Advanced Gastric Cancer: A Phase I/II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 150-155.	0.4	40
110	Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. <i>British Journal of Cancer</i> , 2010, 103, 1209-1214.	2.9	141
111	Tracheal cancer treated with a short course of external and endoluminal radio-chemotherapy combined with cetuximab. <i>Journal of Contemporary Brachytherapy</i> , 2010, 4, 160-162.	0.4	3
112	Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. <i>Journal of Clinical Pathology</i> , 2010, 63, 867-872.	1.0	83
113	The "stone-like" pattern of autophagy in human epithelial tumors and tumor-like lesions: An approach to the clinical outcome. <i>Autophagy</i> , 2010, 6, 830-833.	4.3	21
114	LC3A-Positive Light Microscopy Detected Patterns of Autophagy and Prognosis in Operable Breast Carcinomas. <i>American Journal of Pathology</i> , 2010, 176, 2477-2489.	1.9	101
115	Angiogenesis and angiogenic factor expression in thyroid cancer. <i>Journal of BU on</i> , 2010, 15, 357-61.	0.4	3
116	Hypoxia and activated VEGF/receptor pathway in multiple myeloma. <i>Anticancer Research</i> , 2010, 30, 2831-6.	0.5	48
117	Postoperative Accelerated Radiotherapy with Cytoprotection Followed by Three-Dimensional Conformal Boost in Patients with Early Endometrial/Cervical Cancer. <i>Tumori</i> , 2009, 95, 455-460.	0.6	5
118	Lactate Dehydrogenase 5 Expression in Squamous Cell Head and Neck Cancer Relates to Prognosis following Radical or Postoperative Radiotherapy. <i>Oncology</i> , 2009, 77, 285-292.	0.9	82
119	Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab. <i>Clinical Cancer Research</i> , 2009, 15, 7069-7076.	3.2	52
120	Serum and Tissue LDH Levels in Patients with Breast/Gynaecological Cancer and Benign Diseases. <i>Gynecologic and Obstetric Investigation</i> , 2009, 67, 162-168.	0.7	87
121	Radiation-induced autophagy in normal and cancer cells: Towards novel cytoprotection and radio-sensitization policies?. <i>Autophagy</i> , 2009, 5, 442-450.	4.3	120
122	Serum C-reactive Protein (CRP) Levels in Cancer Patients are Linked with Tumor Burden and are Reduced by Anti-hypertensive Medication. <i>Inflammation</i> , 2009, 32, 169-175.	1.7	26
123	Optimal timing for adjuvant radiation therapy in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 102-116.	2.0	70
124	Hypofractionated and Accelerated Radiotherapy With Subcutaneous Amifostine Cytoprotection as Short Adjuvant Regimen After Breast-Conserving Surgery: Interim Report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1173-1180.	0.4	14
125	Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer. <i>International Journal of Radiation Biology</i> , 2009, 85, 96-104.	1.0	8
126	Computed Tomography Assessment of Lung Density in Patients With Lung Cancer Treated With Accelerated Hypofractionated Radio-Chemotherapy Supported With Amifostine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 258-261.	0.6	5



#	ARTICLE	IF	CITATIONS
127	Colorectal Cancer: Lactate Dehydrogenase (LDH) Activity as a Prognostic Marker. , 2009, , 241-253.		4
128	Erythropoietin receptors in endometrial carcinoma as related to HIF1{alpha} and VEGF expression. In Vivo, 2009, 23, 699-703.	0.6	9
129	Postoperative accelerated radiotherapy with cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer. Tumori, 2009, 95, 455-60.	0.6	1
130	Phosphorylated VEGFR2/KDR receptors are widely expressed in B&Ccell non&C Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematological Oncology, 2008, 26, 219-224.	0.8	30
131	The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecologic Oncology, 2008, 110, 216-221.	0.6	98
132	Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Letters, 2008, 262, 87-93.	3.2	22
133	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia and Lymphoma, 2008, 49, 2181-2186.	0.6	18
134	Hypoxia inducible factor (HIF1&pm and HIF2&pm) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. International Journal of Radiation Biology, 2008, 84, 47-52.	1.0	42
135	A plesiotherapy technique for the post&Coperative treatment of skin cancer using Ir192 microSelectron.. Journal of Applied Clinical Medical Physics, 2008, 9, 211-213.	0.8	0
136	Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study. Anticancer Research, 2008, 28, 3035-40.	0.5	2
137	The pathology of tumor stromatogenesis. Cancer Biology and Therapy, 2007, 6, 639-645.	1.5	44
138	Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1&pm phenotype. Cancer Biology and Therapy, 2007, 6, 153-155.	1.5	4
139	Lung cancer: An organized cellular and metabolic domain. Cancer Biology and Therapy, 2007, 6, 1472-1475.	1.5	88
140	BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1&A pathway and prognosis. Journal of Clinical Pathology, 2007, 61, 217-220.	1.0	34
141	HIF-1 regulates heritable variation and allele expression phenotypes of the macrophage immune response gene SLC11A1 from a Z-DNA&C-forming microsatellite. Blood, 2007, 110, 3039-3048.	0.6	65
142	Early Antivascular Effects of Bevacizumab Anti-VEGF Monoclonal Antibody on Colorectal Carcinomas Assessed With Functional CT Imaging. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 315-318.	0.6	50
143	Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection for Invasive Bladder Cancer. Urology, 2007, 69, 245-250.	0.5	10
144	Long-Term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers in Surgery and Medicine, 2007, 39, 394-402.	1.1	64

#	ARTICLE	IF	CITATIONS
145	Effect of Amifostine on Response Rates in Locally Advanced Non-Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 111-118.	0.4	35
146	Activated Vegfr2/kdr Pathway In Tumour Cells And Tumour Associated Vessels Of Colorectal Cancer. <i>European Journal of Clinical Investigation</i> , 2007, 37, 878-886.	1.7	75
147	Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. <i>Anticancer Research</i> , 2007, 27, 3625-31.	0.5	15
148	Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma. <i>Cancer Research</i> , 2006, 66, 632-637.	0.4	406
149	C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1 $\alpha$ gene define HIF-1 $\alpha$ protein expression in non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 257-262.	0.9	35
150	Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. <i>Anti-Cancer Drugs</i> , 2006, 17, 133-138.	0.7	20
151	Angiogenesis in Colorectal Cancer: Prognostic and Therapeutic Implications. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 408-417.	0.6	73
152	Computed Tomography (CT) Scan Evaluation of Late Toxicity Following Hypofractionated/Accelerated Radiotherapy With Cytoprotection (HypoARC) in Breast Cancer Patients Treated With Conservative Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 479-483.	0.6	4
153	Hypoxia-Inducible Factor-2 $\alpha$ (HIF-2 $\alpha$ ) Induces Angiogenesis in Breast Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2006, 14, 78-82.	0.6	29
154	Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. <i>Cancer Science</i> , 2006, 97, 582-588.	1.7	53
155	Oxygen and glucose consumption in gastrointestinal adenocarcinomas: Correlation with markers of hypoxia, acidity and anaerobic glycolysis. <i>Cancer Science</i> , 2006, 97, 1056-1060.	1.7	54
156	Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1 $\alpha$ expression. <i>Modern Pathology</i> , 2006, 19, 9-16.	2.9	51
157	Phosphorylated KDR expression in endometrial cancer cells relates to HIF1 $\alpha$ /VEGF pathway and unfavourable prognosis. <i>Modern Pathology</i> , 2006, 19, 701-707.	2.9	38
158	Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1281-1293.	0.4	290
159	Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. <i>Gynecologic Oncology</i> , 2006, 103, 912-918.	0.6	88
160	Node-related factors and survival in node-positive breast carcinomas. <i>Breast</i> , 2006, 15, 382-389.	0.9	21
161	Hypoxia inducible factors 1 $\alpha$ and 2 $\alpha$ are associated with VEGF expression and angiogenesis in gallbladder carcinomas. <i>Journal of Surgical Oncology</i> , 2006, 94, 242-247.	0.8	40
162	Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 4301-4308.	0.8	183

#	ARTICLE	IF	CITATIONS
163	Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha) Tj ETQq1 1 0.784314 rgBT /Overlo Recruited in the CHART Randomized Trial. Journal of Clinical Oncology, 2006, 24, 727-735.	0.8	276
164	Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer. Medical Physics, 2006, 34, 76-80.	1.6	7
165	External beam radiotherapy for prostate cancer: current position and trends. Anticancer Research, 2006, 26, 485-94.	0.5	11
166	Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy. Anticancer Research, 2006, 26, 2437-43.	0.5	12
167	Hypofractionated Accelerated Radiotherapy With Cytoprotection Combined With Trastuzumab, Liposomal Doxorubicine, and Docetaxel in c-erbB-2???Positive Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 495-500.	0.6	25
168	Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clinical and Experimental Metastasis, 2005, 22, 25-30.	1.7	198
169	Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. Journal of Clinical Pathology, 2005, 58, 1033-1038.	1.0	50
170	LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. Journal of Clinical Pathology, 2005, 58, 202-206.	1.0	97
171	Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer. Clinical Cancer Research, 2005, 11, 8653-8660.	3.2	35
172	Pyruvate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression in Non Small Cell Lung Cancer and Tumor-Associated Stroma. Neoplasia, 2005, 7, 1-6.	2.3	179
173	Preventing radiation induced xerostomia. Cancer Treatment Reviews, 2005, 31, 546-554.	3.4	25
174	âœStromatogenesisâœand Tumor Progression. International Journal of Surgical Pathology, 2004, 12, 1-9.	0.4	43
175	BNIP3 Expression Is Linked with Hypoxia-Regulated Protein Expression and with Poor Prognosis in NonâœSmall Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 5566-5571.	3.2	129
176	Tumour angiogenic activity and vascular survival ability in bladder carcinoma. Journal of Clinical Pathology, 2004, 57, 250-255.	1.0	11
177	c-erbB-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1Î± Dependent. Clinical Cancer Research, 2004, 10, 7972-7977.	3.2	77
178	Tumour angiogenesis: vascular growth and survival. Apmis, 2004, 112, 431-440.	0.9	72
179	Angiogenesis and vascular survival ability in ovarian adenocarcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 521-526.	1.4	2
180	Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 67-71.	0.4	39

#	ARTICLE	IF	CITATIONS
181	Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 $\alpha$ . Cancer Chemotherapy and Pharmacology, 2004, 53, 8-14.	1.1	29
182	Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. International Journal of Cancer, 2004, 108, 620-627.	2.3	28
183	Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethylol (amifostine) cutaneous treatment advisory panel (ECTAP). International Journal of Radiation Oncology Biology Physics, 2004, 60, 302-309.	0.4	28
184	VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer, 2004, 46, 293-298.	0.9	246
185	Interferon regulatory factor-1 (IRF-1) suppression and derepression during endometrial tumorigenesis and cancer progression. Cytokine, 2004, 26, 164-168.	1.4	12
186	Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience. Anticancer Research, 2004, 24, 3239-43.	0.5	11
187	Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer. , 2003, 74, 357-374.		1
188	Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunology, Immunotherapy, 2003, 52, 127-131.	2.0	14
189	Vascular endothelial growth factor in inflammatory bowel disease. International Journal of Colorectal Disease, 2003, 18, 418-422.	1.0	60
190	Amifostine: is there evidence of tumor protection?. Seminars in Oncology, 2003, 30, 18-30.	0.8	49
191	DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. Journal of Pathology, 2003, 200, 222-228.	2.1	78
192	The vascular network of tumours ? what is it not for?. Journal of Pathology, 2003, 201, 173-180.	2.1	59
193	Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. British Journal of Cancer, 2003, 89, 877-885.	2.9	328
194	Lactate Dehydrogenase Isoenzymes 1 and 5: Differential Expression by Neoplastic and Stromal Cells in Non-Small Cell Lung Cancer and Other Epithelial Malignant Tumors. Tumor Biology, 2003, 24, 199-202.	0.8	100
195	Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. European Journal of Surgical Oncology, 2003, 29, 879-883.	0.5	41
196	Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Research, 2003, 5, R193.	2.0	164
197	Hypoxia inducible factor 1 $\alpha$ and 2 $\alpha$ overexpression in inflammatory bowel disease. Journal of Clinical Pathology, 2003, 56, 209-213.	1.0	184
198	Angiogenesis Relates to Estrogen Receptor Negativity, c-erbB-2 Overexpression and Early Relapse in Node-Negative Ductal Carcinoma of the Breast. International Journal of Surgical Pathology, 2003, 11, 29-34.	0.4	34

#	ARTICLE	IF	CITATIONS
199	Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?. <i>British Journal of Cancer</i> , 2003, 88, 711-717.	2.9	17
200	Hypoxia-inducible factors 1?? and 2?? are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. <i>Melanoma Research</i> , 2003, 13, 493-501.	0.6	151
201	Phytobezoars as a cause of small bowel obstruction associated with a carcinoid tumor of the ileocecal area: Report of a case. <i>Acta Chirurgica Iugoslavica</i> , 2003, 50, 131-133.	0.0	3
202	The effect of trastuzumab/docetaxel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?. <i>Anticancer Research</i> , 2003, 23, 1673-80.	0.5	21
203	Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. <i>Cancer Research</i> , 2003, 63, 5376-80.	0.4	146
204	Concurrent administration of Docetaxel and StealthÂ® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. <i>British Journal of Cancer</i> , 2002, 87, 385-392.	2.9	49
205	Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. <i>British Journal of Cancer</i> , 2002, 86, 1465-1471.	2.9	34
206	Reply: 99mTc-labelled Stealth liposomal doxorubicin (CaelyxÂ®) in glioblastomas and metastatic brain tumours. <i>British Journal of Cancer</i> , 2002, 86, 660-661.	2.9	2
207	Thymidine Phosphorylase Expression in Gallbladder Adenocarcinomas. <i>International Journal of Surgical Pathology</i> , 2002, 10, 181-188.	0.4	13
208	Amifostine in clinical oncology: current use and future applications. <i>Anti-Cancer Drugs</i> , 2002, 13, 181-209.	0.7	127
209	Prognostic Role of Angiogenesis in Operable Carcinoma of the Gallbladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 38-41.	0.6	27
210	Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. <i>Seminars in Oncology</i> , 2002, 29, 14-21.	0.8	7
211	Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer. <i>Seminars in Oncology</i> , 2002, 29, 42-46.	0.8	6
212	Association of hypoxia-inducible factors 1? and 2? with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. <i>Cancer</i> , 2002, 95, 1055-1063.	2.0	207
213	Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. <i>Histopathology</i> , 2002, 40, 92-100.	1.6	37
214	Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 144-155.	0.4	28
215	Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1192-1202.	0.4	311
216	Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. <i>Journal of Pathology</i> , 2002, 196, 416-422.	2.1	50

#	ARTICLE	IF	CITATIONS
217	Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. <i>Clinical and Experimental Metastasis</i> , 2002, 19, 673-679.	1.7	12
218	Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. <i>Seminars in Oncology</i> , 2002, 29, 14-21.	0.8	35
219	Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer. <i>Seminars in Oncology</i> , 2002, 29, 42-46.	0.8	15
220	Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. <i>Clinical Cancer Research</i> , 2002, 8, 1185-91.	3.2	19
221	Unexpected toxicity after low-dose docetaxel treatment of a cancer patient with clinically latent HCV-positive hepatic cirrhosis. <i>Anticancer Research</i> , 2002, 22, 2491-2.	0.5	2
222	Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer. <i>Anticancer Research</i> , 2002, 22, 4137-40.	0.5	9
223	Mean platelet volume: a useful marker of inflammatory bowel disease activity. <i>American Journal of Gastroenterology</i> , 2001, 96, 776-781.	0.2	279
224	Angiogenesis and Apoptosis-Related Protein (p53, bcl-2, and bax) Expression Versus Response of Gastric Adenocarcinomas to Paclitaxel and Carboplatin Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 222-226.	0.6	11
225	The role of 99mTc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. <i>Nuclear Medicine Communications</i> , 2001, 22, 1243-1248.	0.5	10
226	Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 470-477.	1.4	53
227	Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 27-36.	0.4	104
228	The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis. <i>Journal of Pathology</i> , 2001, 194, 101-108.	2.1	87
229	The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma. <i>Cancer</i> , 2001, 92, 2569-2577.	2.0	73
230	Relation of hypoxia inducible factor 1 $\alpha$ and 2 $\alpha$ in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. <i>British Journal of Cancer</i> , 2001, 85, 881-890.	2.9	438
231	Angiogenic Interactions of Vascular Endothelial Growth Factor, of Thymidine Phosphorylase, and of p53 Protein Expression in Locally Advanced Gastric Cancer. <i>Oncology Research</i> , 2001, 12, 33-41.	0.6	30
232	Hypoxia inducible factor (HIF-1 $\alpha$ and HIF-2 $\alpha$ ) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. <i>Cancer Research</i> , 2001, 61, 1830-2.	0.4	199
233	Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy. <i>Anticancer Research</i> , 2001, 21, 663-8.	0.5	13
234	Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. <i>Cancer Research</i> , 2001, 61, 7992-8.	0.4	249

#	ARTICLE	IF	CITATIONS
235	Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. <i>Clinical Cancer Research</i> , 2001, 7, 3399-403.	3.2	147
236	High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae. <i>Anticancer Research</i> , 2001, 21, 2973-8.	0.5	11
237	Tumour angiogenesis and response to radiotherapy. <i>Anticancer Research</i> , 2001, 21, 4285-300.	0.5	47
238	Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. <i>Anticancer Research</i> , 2001, 21, 4301-9.	0.5	37
239	Invading edge vs. inner (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. <i>Journal of Pathology</i> , 2000, 192, 140-149.	2.1	57
240	Docetaxel-induced lymphopenia in patients with solid tumors. <i>Cancer</i> , 2000, 89, 1380-1386.	2.0	52
241	Cancer vascularization: implications in radiotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 545-553.	0.4	86
242	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 313-319.	1.7	8
243	Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2000, 82, 1427-1432.	2.9	252
244	Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. <i>British Journal of Cancer</i> , 2000, 83, 219-224.	2.9	14
245	Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. <i>Medical Oncology</i> , 2000, 17, 135-143.	1.2	10
246	Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 2226-2233.	0.8	243
247	High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. <i>British Journal of Cancer</i> , 2000, 83, 1281-1286.	2.9	162
248	Elevated Thrombopoietin Serum Levels in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 3478-3481.	0.2	37
249	High Intratumoral Accumulation of Stealth Liposomal Doxorubicin in Sarcomas: Rationale for Combination with Radiotherapy. <i>Acta Oncologica</i> , 2000, 39, 207-211.	0.8	116
250	c-erbB-2 and Episialin Challenge Host Immune Response by HLA Class I Expression in Human Non-Small-Cell Lung Cancer. <i>Journal of Immunotherapy</i> , 2000, 23, 104-114.	1.2	11
251	Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. <i>Clinical Cancer Research</i> , 2000, 6, 381-9.	3.2	40
252	Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. <i>Clinical Cancer Research</i> , 2000, 6, 1917-21.	3.2	42

#	ARTICLE	IF	CITATIONS
253	Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. <i>Cancer Research</i> , 2000, 60, 3088-95.	0.4	126
254	Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 3512-3521.	0.8	177
255	Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 107-114.	0.4	39
256	Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. <i>British Journal of Cancer</i> , 1999, 80, 1792-1796.	2.9	52
257	Thymidine phosphorylase expression in endometrial carcinomas. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 445-450.	1.7	23
258	bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 545-554.	1.7	48
259	Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. , 1999, 86, 1421-1430.		80
260	Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. , 1999, 80, 810-817.		32
261	Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). , 1999, 189, 351-357.		46
262	Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. <i>Cancer Letters</i> , 1999, 137, 145-150.	3.2	25
263	Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. <i>Anticancer Research</i> , 1999, 19, 2305-9.	0.5	21
264	Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas?. <i>Oncology Research</i> , 1999, 11, 205-12.	0.6	32
265	Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis. <i>Clinical Cancer Research</i> , 1999, 5, 3970-6.	3.2	16
266	Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 665-672.	1.7	17
267	Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas. <i>Angiogenesis</i> , 1998, 2, 49-55.	3.7	6
268	Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. <i>British Journal of Cancer</i> , 1998, 77, 1696-1703.	2.9	103
269	Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. <i>European Journal of Cancer</i> , 1998, 34, 838-844.	1.3	69
270	MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. <i>Journal of Clinical Pathology</i> , 1998, 51, 667-671.	1.0	94



#	ARTICLE	IF	CITATIONS
271	Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone. <i>Sarcoma</i> , 1998, 2, 25-28.	0.7	2
272	Fractionated Carboplatin Radiosensitization. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 595-601.	0.6	9
273	Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. <i>Anticancer Research</i> , 1998, 18, 71-6.	0.5	16
274	Bcl-2 and p53 expression in stage I endometrial carcinoma. <i>Anticancer Research</i> , 1998, 18, 3689-93.	0.5	9
275	Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. <i>Clinical Cancer Research</i> , 1998, 4, 3017-24.	3.2	94
276	Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 1997, 75, 477-481.	2.9	126
277	Platelet-derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer. , 1997, 181, 196-199.		50
278	Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. , 1997, 74, 565-570.		54
279	Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 1997, 3, 2485-92.	3.2	76
280	The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 315-322.	0.4	80
281	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. , 1996, 179, 80-88.		144
282	Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. <i>Anticancer Research</i> , 1996, 16, 3819-25.	0.5	50
283	LQ-Based Model for Biological Radiotherapy Planning. <i>Medical Dosimetry</i> , 1994, 19, 269-277.	0.4	17